Experiment 380601
Worktypes
Details
| Property | Value |
|---|---|
| Pharmacology | |
| Administration route | ORAL |
| Organism | Piper methysticum (PIPERACEAE) |
| Citation | VOLZ,HP: KIESER,M:. (1997). KAVA-KAVA EXTRACT WS 1490 VERSUS PLACEBO IN ANXIETY DISORDERS-A RANDOMIZED PLACEBO-CONTROLLED 25-WEEK OUTPATIENT TRIAL.. 30() |
| Amount utilized | |
| Compound isolated | |
| Disease | 101 OUTPATIENTS SUFFERING FROM ANXIETY OF NON-PSYCHOTIC ORIGIN (DSM-III-R CRITERIA: AGORAPHOBIA, SPECIFIC PHOBIA, GENERALIZED ANXIETY DISORDER, AND ADJUSTMENT DISORDER WITH ANXIETY) WERE INCLUDED IN A 25-WEEK MULTICENTER RANDOMIZED PLACEBO- CONTROLLED DOUBLE-BLIND TRIAL WITH WS 1490, A SPECIAL EXTRACT OF KAVA-KAVA. IN THE MAIN OUTCOME CRITERION, THE HAMILTON ANXIETY SCALE (HAMA), THERE WAS A SIGNIFIANT SUPERIORITY OF THE TEST DRUG STARTING FROM WEEKS 8 ON. WS 1490 WAS ALSO FOUND TO BE SUPERIOR WITH RESPECT TO THE SECONDARY OUTCOME VARIABLES. HAMA SUBSCORES SOMATIC AND PSYCHIC ANXIETY, CLINICAL GLOBAL IMPRESSION, SELF-REPORT SYMPTOM INVENTORY-90 ITEMS REVISED, AND ADJECTIVE MOOD SCALE ADVERSE EVENTS WERE RARE AND DISTRIBUTED EVENLY IN BOTH GROUPS. |
| Dose amount | 300.0 MG |
| Number | 1 |
| Qualitative result | ACTIVE |
| Animal | HUMAN ADULT |
| Per unit | DAY |
| Dose expression | DOSE |
| Extract | ETOH(100%)EXT |
| Gender | GIVEN TO BOTH SEXES |